Month: March 2020

NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 7,500,000 shares of its common stock, at a price to the public of $0.60 per share. The net proceeds to Seelos from this offering are expected to be approximately $3.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Seelos. Seelos intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates.Benchmark Company acted as sole book-running manager for the offering.The securities described...

VANCOUVER, British Columbia, March 16, 2020 (GLOBE NEWSWIRE) — Patagonia Gold Corp. (“Patagonia” or the “Company”) (TSXV: PGDC) announces the Company has entered into an amending agreement (the “Amending Agreement”) to amend the terms of the option agreement between the Company and Latin Metals Inc. (“Latin Metals”) dated August 12, 2019 (the “Agreement”), pursuant to which the Company has the option to acquire a 100% interest in the past-producing gold / silver Mina Angela property. The Mina Angela property is situated in the Somuncura Massif of southern Argentina and is comprised of 44 individual claims.  It covers 200 km² and is located approximately 50 km east-southeast of Patagonia’s 100% owned Calcatreu gold project.Pursuant to the Amending Agreement, Patagonia has extended the period by which it must enter into a definitive...

COS COB, Conn., March 16, 2020 (GLOBE NEWSWIRE) — Chicken Soup for the Soul Entertainment Inc. (Nasdaq: CSSE), a growing media company building online video-on-demand (“VOD”) networks that provide video content for all screens, today announced it will host a conference call and live webcast to discuss the results of its fourth quarter and full year ended December 31, 2019.Conference Call InformationTo participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.Date, Time: Monday, March 30, 2020, 4:30 p.m. ET.Toll-free: (833) 832-5128International: (484) 747-6583Conference ID: 9597934A live webcast is available at http://ir.cssentertainment.com/ under the “News & Events” tabConference Call Replay InformationToll-free: (855) 859-2056International: (404) 537-3406Reference ID: 9597934ABOUT...

KENNETT SQUARE, Pa., March 16, 2020 (GLOBE NEWSWIRE) — Genesis Healthcare, Inc. (Genesis, or the Company) (NYSE:GEN), one of the largest post-acute care providers in the United States, today announced operating results for the fourth quarter and year ended December 31, 2019. Fourth Quarter and Fiscal Year End 2019 ResultsUS GAAP revenue in the fourth quarter and year ended 2019 was $1.14 billion and $4.57 billion, respectively;  US GAAP net (loss) income attributable to Genesis Healthcare, Inc. in the fourth quarter and year ended 2019 was $(11.4) million and $14.6 million, respectively; Adjusted EBITDA in the fourth quarter and year ended 2019 was $48.5 million and $199.0 million, respectively; and Adjusted EBITDAR in the fourth quarter and year ended 2019 was $146.9 million and $586.1 million, respectively.“We are pleased to report...

Montrouge, France, March 16, 2020DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years                  Conference call today, March 16, at 5:00 PM ET / 10:00 PM CETDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that during its ongoing review of the Biologics License Application (BLA) for investigational Viaskin™ Peanut, it has identified questions regarding efficacy, including the impact of patch-site adhesion. Therefore, the Allergenic Products Advisory Committee (APAC) meeting to discuss the BLA will no longer take place as previously scheduled on May 15, 2020.The Company is in communication with the FDA regarding the potential...

Montrouge, France, le 16 mars, 21 h 30 CET, 2020DBV Technologies fait part d’une nouvelle concernant la revue réglementaire de Viaskin Peanut pour le traitement des enfants âgés de 4 à 11 ansConférence téléphonique aujourd’hui, le 16 mars, à 17h00 ET / 22h00 CETDBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Marché d’actions Nasdaq : DBVT), un laboratoire biopharmaceutique spécialisé dans le développement de médicaments, a annoncé aujourd’hui que la Food and Drug Administration (FDA) des États-Unis avait informé cette dernière que, lors de l’examen de sa demande de licence de produit biologique (BLA) pour le médicament expérimental Viaskin™ Peanut, elle avait identifié des interrogations concernant l’efficacité, et notamment l’impact de l’adhésion locale du patch. Par conséquent, la réunion du Comité...

ATLANTA, March 16, 2020 (GLOBE NEWSWIRE) — UPS continues to deliver for customers even as the Coronavirus uncertainty is requiring greater flexibility and creativity to adapt to new social distancing and other health maintenance protocols.  Recently, the White House through the U.S. task force in response to the Coronavirus asked UPS to assist with logistics planning and operations to support the drive-up patient test facilities in several cities.  UPS will assist with test kit deliveries and test sample transportation to labs participating in the new program.“UPS is proud to provide logistics and transportation support to assist with the Administration’s special Coronavirus multi-city testing program.  We stand ready to assist to help keep our communities safe,” said David Abney, UPS Chairman and CEO.  “We are mobilizing our air...

EDGEWOOD, N.Y., March 16, 2020 (GLOBE NEWSWIRE) — CPI Aerostructures, Inc. (CPI Aero®)  (NYSE American: CVU) today announced that it has filed a Form 12b-25 Notification of Late Filing with regard to its Annual Report on Form 10-K for the year ended December 31, 2019. The Company requires additional time to complete a review of its procedures for revenue recognition from contracts with customers for 2018 and 2019 following its February 14, 2020 announcement of an error relating to the Company’s recognition of revenue under ASC Topic 606 that will require it to amend its annual report on Form 10-K for the year ended December 31, 2018 and its quarterly reports on Form 10-Q for the quarters ended March 31, 2018, June 30, 2018, September 30, 2018, March 31, 2019, June 30, 2019, and September 30, 2019 (the “non-reliance periods”), and...